Ke Bingbing, Shen Aidong, Qiu Hui, Li Weiping, Chen Hui, Li Hongwei
Department of Cardiology, Cardiovascular Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Beijing Key Laboratory of Metabolic Disorder Related Cardiovascular Disease, Beijing, China.
Front Cardiovasc Med. 2023 Aug 10;10:1216422. doi: 10.3389/fcvm.2023.1216422. eCollection 2023.
Serum potassium homeostasis plays an important role in myocardial electrical stability, but the impact of altered serum potassium levels on the major adverse cardiovascular and cerebral events (MACCE) in patients with percutaneous coronary intervention (PCI) has not been evaluated.
To evaluate the association between serum potassium level and the risk of MACCE in PCI patients.
This retrospective study involved 8,263 in-patients from a single-center registry who were successfully treated with PCI between January 2003 and December 2020. Clinical data were collected for 24 h after admission. Data were analyzed from June 2003 to December 2021. The primary outcome was MACCE, defined as a composite of all-cause death, myocardial infarction, revascularization, stroke, and heart failure-related hospitalization.
The median [interquartile range (IQR)] follow-up for all patients was 4.0 (2.1, 5.8) years, and 1,632 patients (19.7%) were diagnosed with MACCE. High serum potassium levels were associated with a 20% increased risk of MACCE (hazard ratio [HR]: 1.20, 95% confidence interval [CI]: 1.05-1.38, = 0.008) and 72% increased risk of all-cause death (HR: 1.72, 95% CI: 1.39-2.14, < 0.001). Multivariate Cox analysis showed that the risk of MACCE was higher in patients at the highest quartile of serum potassium (Q4 vs. Q1: adjusted HR: 1.18, 95% CI: 1.02-1.35, = 0.026). Moreover, a higher serum potassium level was always associated with a higher risk of all-cause death (Q4 vs. Q1: adjusted HR: 1.50, 95% CI: 1.17-1.91, = 0.001). A U-shaped relationship between serum potassium levels, MACCE, and all-cause death was derived in patients undergoing PCI. Serum potassium levels, maintained within the range of 3.8-4.0 mmol/L before PCI, exhibited the lowest risk of associated MACCE and all-cause death.
Our results demonstrate that the serum potassium level could be associated with higher risks of MACCE and all-cause death in PCI patients. In particular, serum potassium levels maintained at 3.8-4.0 mmol/L before PCI could lower the risk of MACCE and all-cause death.
血清钾稳态在心肌电稳定性中起重要作用,但血清钾水平改变对经皮冠状动脉介入治疗(PCI)患者主要不良心血管和脑血管事件(MACCE)的影响尚未得到评估。
评估PCI患者血清钾水平与MACCE风险之间的关联。
这项回顾性研究纳入了2003年1月至2020年12月期间在单中心登记处成功接受PCI治疗的8263例住院患者。入院后24小时收集临床数据。数据于2003年6月至2021年12月进行分析。主要结局为MACCE,定义为全因死亡、心肌梗死、血运重建、中风和心力衰竭相关住院的综合结果。
所有患者的中位随访时间[四分位间距(IQR)]为4.0(2.1,5.8)年,1632例患者(19.7%)被诊断为MACCE。高血清钾水平与MACCE风险增加20%相关(风险比[HR]:1.20,95%置信区间[CI]:1.05-1.38,P = 0.008),与全因死亡风险增加72%相关(HR:1.72,95%CI:1.39-2.14,P < 0.001)。多变量Cox分析显示,血清钾处于最高四分位数的患者发生MACCE的风险更高(Q4与Q1相比:调整后HR:1.18,95%CI:1.02-1.35,P = 0.026)。此外,较高的血清钾水平始终与较高的全因死亡风险相关(Q4与Q1相比:调整后HR:1.50,95%CI:1.17-1.91,P = 0.001)。在接受PCI的患者中,血清钾水平、MACCE和全因死亡之间呈U形关系。PCI前血清钾水平维持在3.8-4.0 mmol/L范围内,发生相关MACCE和全因死亡的风险最低。
我们的结果表明,血清钾水平可能与PCI患者发生MACCE和全因死亡的较高风险相关。特别是,PCI前血清钾水平维持在3.8-4.0 mmol/L可降低MACCE和全因死亡的风险。